Blood pressure medication recalls
82 FDA-recorded recalls of blood pressure medications, most recent Jun 2026 — newest first, straight from the FDA's own database.
Most blood pressure recalls of the last several years have been driven by nitrosamine impurities (NDMA, NDEA) — probable carcinogens found as manufacturing by-products in the ARB class (valsartan, then losartan and irbesartan). Others are ordinary manufacturing or potency failures. A recall almost always names specific lots and manufacturers; a drug being on this list does not mean every bottle is affected.
Chlorthalidone Tablets
Class IIFailed Dissolution Specifications
Inventia Healthcare Limited · Jun 24, 2026
Amlodipine and Olmesartan Medoxomil Tablets
Class IIFailed Dissolution Specifications: Olmesartan Medoxomil content below specifications
Ascend Laboratories, LLC · Jun 10, 2026
Ascend Laboratories
Class IIFailed Dissolution Specifications
Ascend Laboratories, LLC · May 20, 2026
Enalapril Maleate Tablets
Class IIFailed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test
JB Chemicals and Pharmaceuticals Ltd · May 13, 2026
Prazosin Hydrochloride Capsules
Class IIcGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.
Appco Pharma LLC · Apr 8, 2026
Prazosin Hydrochloride Capsules
Class IIcGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.
Appco Pharma LLC · Apr 8, 2026
Prazosin Hydrochloride Capsules
Class IIcGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.
Appco Pharma LLC · Apr 8, 2026
Clonidine Transdermal System
Class IICGMP Deviations: use of an unapproved raw material
Teva Pharmaceuticals USA, Inc · Apr 15, 2026
Clonidine Transdermal System
Class IICGMP Deviations: use of an unapproved raw material
Teva Pharmaceuticals USA, Inc · Apr 15, 2026
Clonidine Transdermal System
Class IICGMP Deviations: use of an unapproved raw material
Teva Pharmaceuticals USA, Inc · Apr 15, 2026
Metoprolol Succinate Extended-Release Tablets
Class IIFailed Dissolution Specifications
Teva Pharmaceuticals USA, Inc · Mar 11, 2026
Metoprolol Succinate Extended-Release Tablets
Class IIFailed Dissolution Specifications
Teva Pharmaceuticals USA, Inc · Mar 11, 2026
Metoprolol Succinate Extended-Release Tablets
Class IIFailed Dissolution Specifications
Teva Pharmaceuticals USA, Inc · Mar 11, 2026
Metoprolol Succinate Extended-Release Tablets
Class IIFailed Dissolution Specifications
Teva Pharmaceuticals USA, Inc · Mar 11, 2026
Bisoprolol Fumarate and Hydrochlorothiazide tablets
Class IIcGMP Deviations: recall due to not meeting the N-Nitroso Bisoprolol impurity specification limits.
Unichem Pharmaceuticals USA Inc. · Feb 11, 2026
Doxazosin Tablets
Class IIITablets/Capsules Imprinted with Wrong ID
Unichem Pharmaceuticals USA Inc. · Feb 18, 2026
Bisoprolol Fumarate and Hydrochlorothiazide Tablets
Class IIICross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe
Glenmark Pharmaceuticals Inc., USA · Dec 10, 2025
Nebivolol Tablets
Class IIICross Contamination with Other Products
Glenmark Pharmaceuticals Inc., USA · Dec 17, 2025
Prazosin Hydrochloride
Class IIFailed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
Amerisource Health Services LLC · Nov 5, 2025
Prazosin Hydrochloride
Class IIFailed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
Amerisource Health Services LLC · Nov 5, 2025
Prazosin Hydrochloride
Class IIFailed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
Amerisource Health Services LLC · Nov 5, 2025
R.E.C.K. (Ropivacaine HCl
Class IIPresence of Particulate Matter
QuVa Pharma, Inc. · Nov 5, 2025
Prazosin Hydrochloride
Class IICGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
Teva Pharmaceuticals USA, Inc · Nov 5, 2025
Prazosin Hydrochloride
Class IICGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
Teva Pharmaceuticals USA, Inc · Nov 5, 2025
Prazosin Hydrochloride
Class IICGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
Teva Pharmaceuticals USA, Inc · Nov 5, 2025
Carvedilol Tablets USP
Class IICGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm
The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · Aug 27, 2025
Carvedilol Tablets
Class IICGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.
Glenmark Pharmaceuticals Inc., USA · Aug 20, 2025
Carvedilol Tablets
Class IICGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.
Glenmark Pharmaceuticals Inc., USA · Aug 20, 2025
Carvedilol Tablets
Class IICGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.
Glenmark Pharmaceuticals Inc., USA · Aug 20, 2025
Carvedilol Tablets
Class IICGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm
Glenmark Pharmaceuticals Inc., USA · Aug 20, 2025
Metoprolol Tartrate Tablets
Class IICGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level.
Westminster Pharmaceuticals LLC · Aug 20, 2025
Metoprolol Tartrate Tablets
Class IICGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level.
Westminster Pharmaceuticals LLC · Aug 20, 2025
Carvedilol Tablets
Class IICGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm
Glenmark Pharmaceuticals Inc., USA · Aug 20, 2025
Spironolactone Tablets
Class IIPresence of foreign substance: identified as aluminum.
SUN PHARMACEUTICAL INDUSTRIES INC · Aug 13, 2025
Amlodipine and Olmesartan Medoxomil Tablets
Class IIFailed Dissolution Specifications: low dissolution results
Ascend Laboratories, LLC · Aug 20, 2025
Amlodipine and Benazepril HCl Capsules USP 2.5 mg/10 mg
Class IILabeling: Incorrect or Missing Lot and/or Exp Date: released with wrong expiry date as Feb.2027 instead of Jan.2027
Lupin Pharmaceuticals Inc. · Aug 6, 2025
Metoprolol Succinate Extended-Release Tablets
Class IIFailed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH) long-term.
Granules Pharmaceuticals Inc. · Jul 9, 2025
Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg
Class IIProduct Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.
Lupin Pharmaceuticals Inc. · Jul 23, 2025
Chlorthalidone Tablets
Class IIFailed Dissolution Specifications
AvKARE · Jun 18, 2025
niCARdipine Hydrochloride Injection
Class IILack of sterility assurance: Product leakage around the vial neck, which could potentially result in a lack of sterility assurance.
American Regent, Inc. · May 7, 2025
niCARdipine Hydrochloride Injection
Class IILack of sterility assurance: Product leakage around the vial neck, which could potentially result in a lack of sterility assurance.
American Regent, Inc. · May 7, 2025
Carvedilol Tablets
Class IICGMP Deviations
Glenmark Pharmaceuticals Inc., USA · Apr 16, 2025
Diltiazem Hydrochloride Extended-Release Capsules 12HR 120mg
Class IICGMP Deviations
Glenmark Pharmaceuticals Inc., USA · Apr 16, 2025
Carvedilol Tablets USP 3.125mg Tablets a.)100-count bottle (NDC 68462-162-01)
Class IICGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
Glenmark Pharmaceuticals Inc., USA · Jun 4, 2025
Carvedilol Tablets USP 12.5 mg
Class IICGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
Glenmark Pharmaceuticals Inc., USA · Jun 4, 2025
Carvedilol Tablets USP 25 mg
Class IICGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
Glenmark Pharmaceuticals Inc., USA · Jun 4, 2025
Carvedilol Tablets USP 6.25 mg
Class IICGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
Glenmark Pharmaceuticals Inc., USA · Jun 4, 2025
HydrALAZINE Hydrochloride
Class IIFailed Impurities/Degradation Specifications
SKY PACKAGING · Feb 12, 2025
HydrALAZINE Hydrochloride
Class IIFailed Impurities/Degradation Specifications
SKY PACKAGING · Feb 12, 2025
Carvedilol 25 mg Tablet
Class IICGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.
RemedyRepack Inc. · Feb 12, 2025
Carvedilol Tablets
Class IICGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit.
Glenmark Pharmaceuticals Inc., USA · Feb 12, 2025
Carvedilol Tablets
Class IICGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit.
Glenmark Pharmaceuticals Inc., USA · Feb 12, 2025
Irbesartan Tablets USP
Class IIOut of Specification for Dissolution
AvKARE · Feb 19, 2025
Cardura XL (doxazosin) extended release tablets 8 mg
Class IIFailed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
Viatris Inc · Jan 22, 2025
Cardura XL (doxazosin) extended release tablets 4 mg
Class IIFailed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
Viatris Inc · Jan 22, 2025
Nebivolol Tablets
Class IICGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.
Aurobindo Pharma USA Inc · Dec 25, 2024
Lisinopril Tablets
Class IIPresence of Foreign Object: A pharmacist discovered a metal fragment embedded in a lisinopril 10 mg tablet.
Evaric Pharmaceuticals Inc. · Nov 27, 2024
Hydralazine HCl Tablets
Class IIIFailed Impurities/Degradation Specifications; during routine stability testing for impurities.
The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · Nov 20, 2024
Diltiazem Hydrochloride Extended-Release Capsules
Class IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.
Glenmark Pharmaceuticals Inc., USA · Dec 11, 2024
Diltiazem Hydrochloride Extended-Release Capsules
Class IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.
Glenmark Pharmaceuticals Inc., USA · Dec 11, 2024
How to use this page
A drug appearing here does not mean your prescription is unsafe. Recalls name specific lots and manufacturers — open the recall to see the affected lot numbers, and match them against your bottle. Never stop a blood-pressure, cholesterol, diabetes, antidepressant or antibiotic medicine on your own because of a recall; confirm your lot, then ask your pharmacist for a replacement if it is affected.
Other categories: Eye drop and ophthalmic · Cholesterol medication · Diabetes medication · Antidepressant · Antibiotic. See also the full recalls tracker and the recall report.
Source: the openFDA drug Enforcement (recall) database. Recalls are matched to this category by the drug names in the FDA’s product description; a small number of category recalls may be missed if the description omits the ingredient. Figures are recall events, not units, and reflect our copy of the FDA data, refreshed daily. This is public regulatory data, not medical advice.